Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

NCT02437370 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter
Recurrent Bladder Carcinoma
Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter
Regional Urothelial Carcinoma of the Renal Pelvis and Ureter
Stage III Bladder Urothelial Carcinoma
Stage III Urethral Cancer
Stage IV Bladder Urothelial Carcinoma
Stage IV Urethral Cancer
Urethral Urothelial Carcinoma

Interventions

DRUG: Pembrolizumab
DRUG: Docetaxel
DRUG: Gemcitabine Hydrochloride

Sponsor

University of California, Davis

Collaborators

[object Object]